Cinclus Pharma
Cinclus Pharma is a clinical-stage pharmaceutical company developing small molecules for the treatment of gastric acid-related diseases. Its lead drug candidate, linaprazan glurate, is a Potassium-Competitive Acid Blocker (PCAB) designed to provide improved management of gastroesophageal reflux disease (GERD) and Helicobacter Pylori infections. The company targets patients who do not achieve sufficient disease control with traditional Proton Pump Inhibitors.
Biotech
Pharmaceuticals
Healthcare
Funding summary
- Total raised
- €71.2M
- Funding rounds
- 2
Investors in Cinclus Pharma
Investors on record for Cinclus Pharma. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Cinclus Pharma?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors